Adaptive Biotechnologies Corporation · NASDAQ:ADPT
Adaptive Biotechnologies — JPM 2021 Healthcare Conference
26 slides from Adaptive Biotechnologies's conference presentation, January 2021
Slide 1: Powering the Age of Immune Medicine
Powering the Age of Immune Medicine JPM 2021 Healthcare Conference
Slide 2: Safe Harbor
Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements co
Slide 3: Using the immune system as the source-code for immune medicine
Using the immune system as the source-code for immune medicine IMMUNE SYSTEM IMMUNE MEDICINE T Cells Research, GENETICS DATA Diagnostics, Drug Discovery B Cells 3
Slide 4: We translate the genetics of the immune system into clinical products
We translate the genetics of the immune system into clinical products “One” Immune Medicine Synergistic Data Interplay Immune Medicine Products Platform Life Science Clinical Drug Clinical Research Diagnostics Discovery Diagnostics CELLULAR THERAPIES IMMUNO MRD SEQUENCING MONITORING Immune Receptor
Slide 5: Immune receptor data leads to products across multiple business areas: COVID-19
Immune receptor data leads to products across multiple business areas COVID-19 COVID: 1st launched indication- confirms recent or prior infection Clinical Diagnostics T-Cell B-Cell COVID Life Science Data Drug Research Discovery immunoSEQ T-MAP COVID Neutralizing antibodies Annotate immunoSEQ sample
Slide 6: Immune receptor data leads to products across multiple business areas: Cancer
Immune receptor data leads to products across multiple business areas CANCER Cancer: early and accurate detection, MRD monitoring Clinical Diagnostics Cancer TCRs Life Science Drug Research Discovery immunoSEQ T-MAP Cancer Cell Therapy Cancer Mapping TCRs to cancer antigens for Identifying optimal c
Slide 7: Uniquely positioned as an immune medicine product development engine
Uniquely positioned as an immune medicine product development engine Moats Around our Platform Broad Applications with >$54B TAM1 CANCER Speed INFECTIOUS AUTOIMMUNE DISEASE DISORDERS Scale Clinically validated Computational CNS ALLERGY Clinical Precision DISORDERS INFLAMMATION technology and biology
Slide 8: Multiple opportunities for growth
Multiple opportunities for growth ALL* Academic (RUO) Life Sciences Diagnostics: MM* Research clonoSEQ Pharma (RUO) CLL* T-MAP NHL** COVID-19 ** Oncology†† Lyme† Cell Therapy Accurate Auto- Detection immune GI Diseases† Neutralizing COVID-19††† Antibodies Diagnostics: Ovarian† Drug Discovery T-cell
Slide 9: Life Science Research: immunoSEQ
Life Science Research immunoSEQ
Slide 10: immunoSEQ, quantifying immunology
immunoSEQ, quantifying immunology Repertoire T-Cell Public Mapping LIFE SCIENCE RESEARCH Properties Fraction Clones immunoSEQ immunoSEQ T-MAP ◼ Pioneer of immunosequencing ◼ Mapping T-cell immune responses to specific antigens ◼ Used by >2,4001 researchers; by >165 1 biopharma ◼ immunoSEQ T-MAP COVI
Slide 11: Clinical Diagnostics: clonoSEQ
Clinical Diagnostics clonoSEQ
Slide 12: clonoSEQ, MRD monitoring gold standard in blood cancer
clonoSEQ, MRD monitoring gold standard in blood cancer MULTIPLE Counts remaining patient specific MYELOMA cancerous cells after treatment CLINICAL DIAGNOSTICS MRD Clinical Testing MRD Pharma Trials ◼ FDA cleared in MM, ALL (bone marrow) and CLL ◼ Test of choice >40 biopharma companies in >190 (bone
Slide 13: Unprecedented number of clonoSEQ abstracts at ASH 2020
Unprecedented number of clonoSEQ abstracts at ASH 2020 ABSTRACT ABSTRACT ABSTRACTS 46 ACCEPTED Data Highlights the Real-World Benefits ◼ Improved PFS following CLINICAL DIAGNOSTICS ORAL Better Outcomes decision to change therapy 18 PRESENTATIONS based on MRD [P=0.006] PHARMA ◼ Strong correlation of
Slide 14: clonoSEQ lifecycle plan focused on increasing access for patients
clonoSEQ lifecycle plan focused on increasing access for patients 4.6M global patients ◼ MM: trial ongoing; data expected in 2021 1 Moving Into Blood ◼ NHL: ongoing ISTs and pharma trials CLINICAL DIAGNOSTICS ◼ Direct-to-patient campaign 2 Increasing Awareness ◼ Watch Registry; our U.S prospective s
Slide 15: Clinical Diagnostics: T-Detect
Clinical Diagnostics T-Detect
Slide 16: T-Detect, a new category of immune-based diagnostics
T-Detect, a new category of immune-based diagnostics + CLINICAL DIAGNOSTICS One Blood Web Scale T-Cell Based Sample TCR- Antigen Map Diagnostic Relevance of T-cells T-Detect Indications ◼ T-cells play a central role in the immune response to any ◼ T-Detect COVID: 1st indication to confirm SARS- dise
Slide 17: First indication, T-Detect COVID
First indication, T-Detect COVID 1st T-Cell Based Test to Confirm Past COVID Infection Go-to-Market Strategy ◼ Targeting self-pay consumers; concierge medicine; CLINICAL DIAGNOSTICS employers; public health agencies T-Cells: Evolved to Detect ◼ Available at T-Detect.com ❑ Implementing “virtual HCP”
Slide 18: Accelerating disease mapping through R&D pipeline
Accelerating disease mapping through R&D pipeline T-Detect Pipeline T-Detect Vision ◼ T-Detect COVID infrastructure enables acceleration of CLINICAL DIAGNOSTICS future indications ◼ Actively evaluating dozens of indications simultaneously to 1 2 3 put into our 5 stage R&D funnel ◼ Moving diseases at
Slide 19: Drug Discovery
Drug Discovery
Slide 20: Drug discovery, identifying best-in-class TCR and BCR candidates
Drug discovery, identifying best-in-class TCR and BCR candidates T-CELL THERAPEUTICS ANTIBODY THERAPEUTICS Hundreds of Millions of Millions of Virus + ANTIGEN + antigens TCRs BCRs Antigens SPECIFICITY BINDING DRUG DISCOVERY Killing Characterize Safety Neutralize IND Enabling studies TCR1 TCR2 … TCRx
Slide 21: Focus on 2nd shared product and scaling private product development
Focus on 2nd shared product and scaling private product development Use the map Private Product Technology Developments, Investments Personalized Approach Patient-specific TCRs DRUG DISCOVERY Clinical Unmet Need 2nd Shared Product 1st Shared Product IND submission Complete TruTCR data package 1st Sh
Slide 22: Potent neutralizing antibodies against COVID delivered from our platform
Potent neutralizing antibodies against COVID delivered from our platform Current environment Our antibodies can solve the current issues ◼ SARS-C0V-2 is likely endemic in our population ◼ Search at scale identifies more potent antibodies against multiple parts of the virus, resulting in: ◼ Virus mut
Slide 23: 2021 Catalysts
2021 Catalysts ◼ Embed T-MAP COVID into SARS-CoV-2 vaccine trials Life Science ◼ Expand immunoSEQ T-MAP data offering into other disease categories Research ◼ Expand distribution of immunoSEQ RUO kit ◼ FDA clearance for clonoSEQ ALL in blood Clinical ◼ T-Detect COVID EUA clearance; commercialization
Slide 24: If you believe in Immune Medicine, believe in Adaptive
If you believe in Immune Medicine, believe in Adaptive ✓ Differentiated vision ✓ Unparalleled science & data ✓ Strong execution record ✓ Diverse & experienced team ✓ Well capitalized
Slide 25: Thank You.
Thank You.
Slide 26: Appendix: Clinical portfolio and pipeline
Appendix: Clinical portfolio and pipeline Diagnostic Signal Clinical FDA FDA Product Plan Discovery Validation Submission Clearance Multiple Myeloma Acute Lymphoblastic Leukemia Monitor MRD: Chronic Lymphocytic Leukemia Non-Hodgkin’s Lymphoma (Subtypes) COVID-19 Accurate Detection: Lyme Disease GI D
Adaptive Biotechnologies — JPM 2021 Healthcare Conference on 6ix